| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Research Abstract |
This research has found a significant positive association between launch delay and success rates of new drug development in the era of global development, which enables us to propose effective R&D policy measures based on the underlying mechanism of profit maximization under uncertainty. We also have found that the global pharmaceutical development and regulatory environment, including implementation of post-marketing surveillance just after launching, seem to have impact on drug safety and dose-setting for the Japanese population. These findings help establish new drug development regulation and policies.
|
